Compare KLA Corp. (KLAC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Tango Therapeutics Inc. — how do they compare? KLA Corp. trades at $175 (market cap $233.35B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: KLA Corp. is far larger — about 62.4× Tango Therapeutics Inc.'s market cap, and KLA Corp. pays a 0.51% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and Tango Therapeutics Inc. for 0 Days on average.
| KLAC | TNGX | |
|---|---|---|
Market Cap | $233.35B | $3.74B |
Volume | 14,457,699 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $301.71 | $32.90 |
52-Week Low | $108.70 | $7.50 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | $234.60B | $2.76B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $184.00, down 3.22% on the day, with strong fundamental performance including 35.57% net income margin and 87.5% ROE. The stock shows bullish technical signals with recent earnings beats and a $12.57 billion backlog driven by AI demand. Revenue grew to $12.16 billion in 2025, with analysts projecting $13.6 billion for 2026.
Outlook remains positive with 63.6% analyst buy ratings and $223.88 consensus price target, representing 22% upside. Key risks include competitive pressures from AMAT and ASML, margin compression, and cyclical semiconductor equipment spending. The company's dominant position in semiconductor inspection equipment supports long-term growth prospects.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
